Precision Medicine and Artificial Intelligence

Michael Mahler received his Ph.D. from the institute of molecular genetics at the University of Heidelberg (Germany). During his Ph.D. thesis, Michael Mahler worked at The Scripps Research Institute in the laboratory of Prof. Mike Pollard and Prof. Eng Tan. He is currently Vice President of Research at Inova Diagnostics. His research is focused on the B-cell autoimmune response in autoimmune diseases and the discovery of novel autoantigens which resulted in more than 300 peer reviewed journal articles as well as several patents. In addition, he works on the development and characterization of novel diagnostic assays for the diagnosis of autoimmune diseases. In the scientific community, he serves as Editor of different scientific journals and as reviewer for more than 40 journals. Michael Mahler became exposed to and interested in Artificial Intelligence as well as Precision Medicine and as a consequence, co-founded the Precision Medicine in Autoimmunity (PMA) (www.precisionmedicineautoimmunity.org) conference.

• 1. History, current status, and future directions of artificial intelligenceOlga Kubassova, Faiq Shaikh, Carlos Melus, and Michael Mahler2. Precision medicine as an approach to autoimmune diseasesMarvin J. Fritzler and Michael Mahler3. Biomarker and data science as integral part of precision medicineCarlos Melus, Brenden Rossin, Mary Ann Aure, and Michael Mahler4. Companion and complementary diagnostics: A key to precision medicineJan Trøst Jørgensen5. Checkpoint inhibitors: Interface of cancer and autoimmunity: Opportunity for second level precision medicineSavino Sciascia, Marie Hudson, Marvin J. Fritzler, Minoru Satoh, and Michael Mahler6. The evolving potential of precision medicine in the management of autoimmune liver diseaseGary L. Norman, Nicola Bizzaro, Danilo Villalta, Diego Vergani, Giorgina Mieli-Vergani, Gideon M. Hirschfield, and Michael Mahler7. Precision medicine in autoimmune diseaseKevin D. Deane8. Development of multi-omics approach in autoimmune diseasesMay Y. Choi, Marvin J. Fritzler, and Michael Mahler9. N-of-1 trials: Implications for clinical practice and personalized clinical trialsJoanne Bradbury and Michael Mahler10. Health risk assessment and family history: Toward disease preventionLily W. Martin, Lauren C. Prisco, Laura Martinez-Prat, Michael Mahler, and Jeffrey A. Sparks11. Regulatory aspects of artificial intelligence and machine learning-enabled software as medical devices (SaMD)Michael Mahler, Carolina Auza, Roger Albesa, Carlos Melus, and Jungen Andrew Wu12. Precision medicine from the patient’s perspective: More opportunities and increasing responsibilitiesKim MacMartin-Moglia and Michael Mahler